Understanding why the brain degenerates in rare metabolic diseases may hold keys to far more common conditions like Parkinson's and Alzheimer's — and a new molecular toolkit developed for studying lysosomal storage disorders (LSDs) could accelerate that translation considerably. The lysosome, long regarded as merely the cell's recycling bin, is now recognized as a central hub of proteostasis, nutrient sensing, and neuronal survival signaling, making dysfunction there a high-value target for broader neurodegeneration research.
Researchers constructed a comprehensive experimental platform using human induced neurons — specifically cortical-like and dopaminergic-like cell types — engineered to model more than 70 distinct LSD classes mapped across over 50 genetic loci. These disorders share a common failure mode: defective lysosomal breakdown of lipids and glycoproteins, leading to toxic intracellular accumulation. By applying systematic proteomics across these disease-relevant cell models, the team generated a comparative atlas of how protein landscapes shift when lysosomal function is compromised in neurons that closely resemble those lost in Alzheimer's and Parkinson's disease, respectively. The approach enables disease-class comparisons that were previously impractical at this resolution and scale.
The significance of this work extends well beyond the rare-disease community. Lysosomal dysfunction is increasingly implicated in sporadic neurodegeneration — GBA1 mutations, which cause Gaucher disease (itself an LSD), are the single most common genetic risk factor for Parkinson's disease. This toolkit effectively creates a Rosetta Stone for deciphering how lysosomal proteome remodeling contributes to neuronal vulnerability. That said, induced neurons, while human-derived and disease-relevant, remain simplified models — they lack the synaptic networks, glial support, and aging signatures of adult brain tissue. The findings are mechanistically rich but require validation in post-mortem tissue and, eventually, longitudinal patient cohorts. This is an incremental but technically sophisticated advance that meaningfully raises the floor for LSD mechanistic research and opens new entry points into the broader neurodegeneration field.